Gossamer Bio Inc

Research Gossamer Bio Inc (GOSS) on Bullrun: market cap USD 38.49M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerGOSS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 38.49M
• Financial periodFY2025
• RevenueUSD 48.47M
• Revenue growth-57.7%
• Net income-USD 170.37M
• Free cash flow-USD 171.35M

Valuation Snapshot

latest market cap is USD 38.49M.

About Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc.

Frequently asked questions

What is Gossamer Bio Inc's market cap?

Gossamer Bio Inc's market capitalization is USD 38.49M.

What does Gossamer Bio Inc do?

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States.